Telbivudine (CAS 3424-98-4)
See product citations (1)
QUICK LINKS
Telbivudine is a synthetic nucleoside analog that is used extensively in virology research, specifically in the study of hepatitis B virus (HBV) replication. It serves as an inhibitor of the HBV polymerase, which is for the virus′s replication process. By incorporating itself into the viral DNA, telbivudine causes chain termination and prevents the virus from further replicating its genetic material. Researchers utilize this compound to understand the molecular dynamics of HBV polymerase inhibition and to explore the resistance mechanisms that the virus may develop. Additionally, telbivudine is used in comparative studies with other nucleoside analogs to assess differences in efficacy and the potential for combination treatments in HBV research. It also plays a role in the investigation of the long-term effects of nucleoside analogs on viral replication and mutation rates.
Telbivudine (CAS 3424-98-4) References
- Telbivudine/Torcitabine Idenix/Novartis. | Hodge, RA. 2004. Curr Opin Investig Drugs. 5: 232-41. PMID: 15043399
- Telbivudine: an upcoming agent for chronic hepatitis B. | Yuen, MF. and Lai, CL. 2005. Expert Rev Anti Infect Ther. 3: 489-94. PMID: 16107194
- Telbivudine in the treatment of chronic hepatitis B. | Hadziyannis, SJ. and Vassilopoulos, D. 2008. Expert Rev Gastroenterol Hepatol. 2: 13-22. PMID: 19072366
- Telbivudine in the treatment of chronic hepatitis B. | Nash, K. 2009. Adv Ther. 26: 155-69. PMID: 19225726
- Telbivudine for the treatment of chronic hepatitis B infection. | Hartwell, D., et al. 2009. Health Technol Assess. 13 Suppl 3: 23-30. PMID: 19846025
- Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. | Hann, HW. 2010. Expert Opin Pharmacother. 11: 2243-9. PMID: 20698726
- Telbivudine: a review of its use in compensated chronic hepatitis B. | McKeage, K. and Keam, SJ. 2010. Drugs. 70: 1857-83. PMID: 20836578
- Telbivudine treatment in chronic hepatitis B: experience from China. | You, H. and Jia, J. 2013. J Viral Hepat. 20 Suppl 1: 3-8. PMID: 23458519
- Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. | Wang, GQ., et al. 2013. J Viral Hepat. 20 Suppl 1: 9-17. PMID: 23458520
- Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. | Liu, H., et al. 2014. Am J Med Sci. 347: 131-8. PMID: 23563307
- Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. | Lu, YP., et al. 2014. Clin Lab. 60: 571-86. PMID: 24779291
- Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. | Kao, JH., et al. 2017. J Gastroenterol Hepatol. 32: 73-81. PMID: 27515408
- Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. | Liu, J., et al. 2017. J Viral Hepat. 24 Suppl 1: 6-11. PMID: 29082653
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Telbivudine, 10 mg | sc-222340 | 10 mg | $138.00 | |||
Telbivudine, 100 mg | sc-222340A | 100 mg | $1092.00 |